TABATA MARUYAMA DOS SANTOS

(Fonte: Lattes)
Índice h a partir de 2011
5
Lattes
Projetos de Pesquisa
Unidades Organizacionais
LIM/20 - Laboratório de Terapêutica Experimental, Hospital das Clínicas, Faculdade de Medicina

Filtros

Limpar filtros

Configurações

Indexador: MEDLINE ×

Resultados de Busca

Agora exibindo 1 - 10 de 22
  • conferenceObject
    Treatment with proteinase inhibitor from Enterolobium contortisiliquum in mice with asthma-COPD
    (2020) BARBOSA, Jessica Anastacia Silva; SILVA, Luana Laura Sales Da; JOAO, Juliana Morelli Lopes Goncalves; SANTOS, Tabata Maruyama Dos; CAMARGO, Leandro Nascimento; CAMPOS, Elaine Cristina De; GALLI, Thiago Tafarel; SARAIVA-ROMANHOLO, Beatriz Mangueira; BEZERRA, Suellen Karoline Moreira; HAMAGUCHI, Sara Sumie Sobral; LEICK, Edna Aparecida; PRADO, Carla Maximo; MARTINS, Milton De Arruda; OLIVO, Maria Luiza Vilela; RIGHETTI, Renato Fraga; TIBERIO, Iolanda De Fatima Lopes Calvo
  • conferenceObject
    Anti-IL17 treatment control responses in lung injury induced by elastase
    (2018) FUKUZAKI, Silvia; GARRIDO, Aurelio C.; RIGHETTI, Renato F.; SANTOS, Tabata M.; CAMARGO, Leandro N.; ARISTOTELES, Luciana R. C. R. B.; SOUZA, Flavia C. R.; SARAIVA-ROMANHOLO, Beatriz M.; LEICK, Edna A.; PRADO, Carla M.; MARTINS, Milton A.; TIBERIO, Iolanda F. L. C.
  • conferenceObject
    Effects of environmental exposure to iron powder in an elastase mice model
    (2022) GALLI, T. Tafarel; CAMPOS, E. C.; SANTOS, T. M.; FUKUZAKI, S.; CAMARGO, L. N.; BEZERRA, S. K. M.; HAMAGUCHI, S. S. S.; SILVA, F. J. A. Da; SARAIVA-ROMANHOLO, B. M.; OLIVO, C. R.; PRADO, C. M.; LOPES, F. Degobbi Tenorio Quirino Dos Santos; LEICK, E. A.; BOUROTTE, C. L. M.; BENSENOR, I. J. M.; LOTUFO, P. A.; RIGHETTI, R. F.; TIBERIO, I. F. L. C.
  • article 0 Citação(ões) na Scopus
    Investigating the Effects of a New Peptide, Derived from the Enterolobium contortisiliquum Proteinase Inhibitor (EcTI), on Inflammation, Remodeling, and Oxidative Stress in an Experimental Mouse Model of Asthma-Chronic Obstructive Pulmonary Disease Overlap (ACO)
    (2023) BARBOSA, Jessica Anastacia Silva; SILVA, Luana Laura Sales da; JOAO, Juliana Morelli Lopes Goncalves; CAMPOS, Elaine Cristina de; FUKUZAKI, Silvia; CAMARGO, Leandro do Nascimento; SANTOS, Tabata Maruyama dos; SANTOS, Henrique Tibucheski dos; BEZERRA, Suellen Karoline Moreira; SARAIVA-ROMANHOLO, Beatriz Mangueira; LOPES, Fernanda Degobbi Tenorio Quirino dos Santos; BONTURI, Camila Ramalho; OLIVA, Maria Luiza Vilela; LEICK, Edna Aparecida; RIGHETTI, Renato Fraga; TIBERIO, Iolanda de Fatima Lopes Calvo
    The synthesized peptide derived from Enterolobium contortisiliquum (pep3-EcTI) has been associated with potent anti-inflammatory and antioxidant effects, and it may be a potential new treatment for asthma-COPD overlap-ACO). Purpose: To investigate the primary sequence effects of pep3-EcTI in an experimental ACO. BALB/c mice were divided into eight groups: SAL (saline), OVA (ovalbumin), ELA (elastase), ACO (ovalbumin + elastase), ACO-pep3-EcTI (treated with inhibitor), ACO-DX (treated with dexamethasone), ACO-DX-pep3-EcTI (treated with dexamethasone and inhibitor), and SAL-pep3-EcTI (saline group treated with inhibitor). We evaluated the hyperresponsiveness to methacholine, exhaled nitric oxide, bronchoalveolar lavage fluid (BALF), mean linear intercept (Lm), inflammatory markers, tumor necrosis factor (TNF-alpha), interferon (IFN)), matrix metalloproteinases (MMPs), growth factor (TGF-beta), collagen fibers, the oxidative stress marker inducible nitric oxide synthase (iNOS), transcription factors, and the signaling pathway NF-kappa B in the airways (AW) and alveolar septa (AS). Statistical analysis was conducted using one-way ANOVA and t-tests, significant when p < 0.05. ACO caused alterations in the airways and alveolar septa. Compared with SAL, ACO-pep3-EcTI reversed the changes in the percentage of resistance of the respiratory system (%Rrs), the elastance of the respiratory system (%Ers), tissue resistance (%Gtis), tissue elastance (%Htis), airway resistance (%Raw), Lm, exhaled nitric oxide (ENO), lymphocytes, IL-4, IL-5, IL-6, IL-10, IL-13, IL-17, TNF-alpha, INF-gamma, MMP-12, transforming growth factor (TGF)-beta, collagen fibers, and iNOS. ACO-DX reversed the changes in %Rrs, %Ers, %Gtis, %Htis, %Raw, total cells, eosinophils, neutrophils, lymphocytes, macrophages, IL-1 beta, IL-6, IL-10, IL-13, IL-17, TNF-alpha, INF-gamma, MMP-12, TGF-beta, collagen fibers, and iNOS. ACO-DX-pep3-EcTI reversed the changes, as was also observed for the pep3-EcTI and the ACO-DX-pep3-EcTI. Significance: The pep3-EcTI was revealed to be a promising strategy for the treatment of ACO, asthma, and COPD.
  • article 2 Citação(ões) na Scopus
    Effects of a Peptide Derived from the Primary Sequence of a Kallikrein Inhibitor Isolated from Bauhinia bauhinioides (pep-BbKI) in an Asthma-COPD Overlap (ACO) Model
    (2023) SILVA, Luana Laura Sales da; BARBOSA, Jessica Anastacia Silva; JOAO, Juliana Morelli Lopes Goncalves; FUKUZAKI, Silvia; CAMARGO, Leandro do Nascimento; SANTOS, Tabata Maruyama dos; CAMPOS, Elaine Cristina de; COSTA, Arthur Silva; SARAIVA-ROMANHOLO, Beatriz Mangueira; BEZERRA, Suellen Karoline Moreira; LOPES, Fernanda Tenorio Quirino dos Santos; BONTURI, Camila Ramalho; OLIVA, Maria Luiza Vilela; LEICK, Edna Aparecida; RIGHETTI, Renato Fraga; TIBERIO, Iolanda de Fatima Lopes Calvo
    (1) There are several patients with asthma-COPD overlap (ACO). A peptide derived from the primary sequence of a kallikrein inhibitor isolated from Bauhinia bauhinioides (pep-BbKI) has potent anti-inflammatory and antioxidant effects. Purpose: To investigate the effects of pep-BbKI treatment in an ACO model and compare them with those of corticosteroids. (2) BALB/c mice were divided into groups: SAL (saline), OVA (ovalbumin), ELA (elastase), ACO (ovalbumin + elastase), ACO-pep-BbKI (treated with inhibitor), ACO-DX (dexamethasone treatment), ACO-DX-pep-BbKI (both treatments), and SAL-pep-BbKI (saline group treated with inhibitor). We evaluated: hyperresponsiveness to methacholine, bronchoalveolar lavage fluid (BALF), exhaled nitric oxide (eNO), IL-1 & beta;, IL-4, IL-5, IL-6, IL-10, IL-13, IL-17, IFN-& gamma;, TNF-& alpha;, MMP-9, MMP-12, TGF-& beta;, collagen fibers, iNOS, eNO, linear mean intercept (Lm), and NF-& kappa;B in airways (AW) and alveolar septa (AS). (3) ACO-pep-BbKI reversed ACO alterations and was similar to SAL in all mechanical parameters, Lm, neutrophils, IL-5, IL-10, IL-17, IFN-& gamma;, TNF-& alpha;, MMP-12 (AW), collagen fibers, iNOS (AW), and eNO (p > 0.05). ACO-DX reversed ACO alterations and was similar to SAL in all mechanical parameters, Lm, total cells and differentials, IL-1 & beta;(AS), IL-5 (AS), IL-6 (AS), IL-10 (AS), IL-13 (AS), IFN-& gamma;, MMP-12 (AS), TGF-& beta; (AS), collagen fibers (AW), iNOS, and eNO (p > 0.05). SAL was similar to SAL-pep-BbKI for all comparisons (p > 0.05). (4) Pep-BbKI was similar to dexamethasone in reducing the majority of alterations of this ACO model.
  • conferenceObject
    Inflammation and remodeling modulated by anti IL17 in model of lung injury induced by elastase in mice
    (2019) LEICK, Edna A.; FUKUZAKI, Silvia; RIGHETTI, Renato F.; SANTOS, Tabata M.; CAMARGO, Leandro N.; GARRIDO, Aurelio C.; ARISTOTELES, Luciana R. C. R. B.; SOUZA, Flavia C. R.; SARAIVA-ROMANHOLO, Beatriz M.; PRADO, Carla M.; MARTINS, Milton A.; TIBERIO, Iolanda F. L. C.
  • conferenceObject
    Cholinergic System in the Exposure of Iron Particles in an Experimental Model of Chronic Allergic Inflammation
    (2023) TIBERIO, I. C.; SANTOS, T. M.; FUKUZAKI, S.; CAMPOS, E.; GALLI, T. T.; SILVA, L. L. S.; BARBOSA, J. A. S.; JOAO, J. M. L. G.; CAMARGO, L. D.; SARAIVA-ROMANHOLO, B. M.; CIRILLO, J. V. O.; BEZERRA, S. K. M.; PRADO, C. M.; MARTINS, M. A.; RIGHETTI, R. F.; LOPES, F. D.; LEICK, E. A.; SILVA, F. J. A.; REZENDE, B. G.; BOUROTTE, C. L. M.; BENSENOR, I. J. M.; LOTUFO, P. A.
  • conferenceObject
    Plant protease inhibitors compared to corticosteroids in mice with Asthma-COPD
    (2020) JOAO, Juliana Morelli Lopes Goncalves; BARBOSA, Jessica Anastacia Silva; SILVA, Luana Laura Sales Da; SANTOS, Tabata Maruyama Dos; CAMARGO, Leandr Do Nascimento; CAMPOS, Elaine Cristina De; GALIL, Thiago Tafarel; SARAIVA-ROMANHOLO, Beatriz Mangueira; BEZERRA, Suellen Karoline Moreira; HAMAGUCHI, Sara Sumie Sobral; MARTINS, Milton De Arruda; OLIVO, Maria Luiza Vilela; RIGHETTI, Renato Fraga; TIBERIO, Iolanda De Fatima Lopes Calvo; LEICK, Edna Aparecida
  • conferenceObject
    Anti-IL-17 Treatment Modulates Pulmonary Responses in Model of Asthma-COPD Overlap
    (2022) CAMARGO, L.; SANTOS, T.; FUKUZAKI, S.; MARTINS, N.; ALMEIDA, F.; LOURENCO, J.; BEZERRA, S.; SARAIVA-ROMANHOLO, B.; PRADO, C.; LOPES, F.; LEICK, E.; RIGHETTI, R.; TIBERIO, I.
  • article 7 Citação(ões) na Scopus
    Preventive and therapeutic effect of anti-IL-17 in an experimental model of elastase-induced lung injury in C57Bl6 mice
    (2021) FUKUZAKI, Silvia; RIGHETTI, Renato Fraga; SANTOS, Tabata Maruyama dos; CAMARGO, Leandro do Nascimento; ARISTOTELES, Luciana R. C. R. B.; SOUZA, Flavia C. R.; GARRIDO, Aurelio C.; SARAIVA-ROMANHOLO, Beatriz Mangueira; LEICK, Edna Aparecida; PRADO, Carla Maximo; MARTINS, Milton de Arruda; TIBERIO, Iolanda de Fatima Lopes Calvo
    Chronic obstructive pulmonary disease (COPD) is an important health care issue, and IL-17 can modulate inflammatory responses. We evaluated preventive and therapeutic effect of anti-interleukin (IL)-17 in a model of lung injury induced by elastase, using 32 male C57Bl6 mice, divided into 4 groups: SAL, ELASTASE CONTROL (EC), ELASTASE I PREVENTIVE ANTI-IL-17 (EP), and ELASTASE + THERAPEUTIC ANTI-IL-17 (ET). On the 29th day, animals were anesthetized with thiopental, tracheotomized, and placed on a ventilator to evaluate lung mechanical, exhaled nitric oxide (eNO), and total cells of bronchoalveolar lavage fluid was collected. We performed histological techniques, and linear mean intercept (Lm) was analyzed. Both treatments with anti-IL-17 decreased respiratory resistance and elastance, airway resistance, elastance of pulmonary parenchyma, eNO, and Lm compared with EC. There was reduction in total cells and macrophages in ET compared with EC. Both treatments decreased nuclear factor-kappa B, inducible nitric oxide synthase, matrix metalloproteinase (MMP)-9, MMP-12, transforming growth factor-beta, tumor necrosis factor-alpha, neutrophils, IL-1 beta, isoprostane, and IL-17 in airways and alveolar septa; collagen fibers, decorin and lumican in airways; and elastic fibers and fibronectin in alveolar septa compared with EC. There was reduction of collagen fibers in alveolar septa and biglycan in airways in EP and a reduction of eNO synthase in airways in ET. In conclusion, both treatments with anti-IL-17 contributed to improve most of parameters evaluated in inflammation and extracellular matrix remodeling in this model of lung injury.